Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G for Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX).
- Disclosed ownership: 6.9%.
- Date of event: 17 Dec 2025.
Affinity Asset Advisors, LLC - 17 Dec 2025 SCHEDULE 13G Report for Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Asset Advisors, LLC
- Symbol
- FBRX
- Shares outstanding
- 12,498,551 shares
- Disclosed Ownership
- 862,400 shares
- Ownership
- 6.9%
- Form type
- SCHEDULE 13G
- Filing time
- 23 Dec 2025, 17:15:46 UTC
- Date of event
- 17 Dec 2025
- Next filing
- 29 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 6.9% ownership in Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX) on 17 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Dec 2025, 17:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 6.9% | 862,400 | 0 | 862,400 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer | |
| Affinity Healthcare Fund, LP | 6.9% | 862,400 | 0 | 862,400 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer |